NCT05225844

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal Cancer With Previous Standard Treatment Failure ：an Exploratory, Single-arm, Open-label, Phase II Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: Harbin Medical University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

At present, surgery, radiotherapy and chemotherapy are the main treatment methods for patients with advanced gastrointestinal cancer. Although targeted therapy has significantly improved the prognosis of patients, the mortality of patients has not been significantly reduced, so new treatment methods are urgently needed. In recent years, immunotherapy has become a new hotspot in tumor therapy. Compared with traditional treatment, immune checkpoint inhibitors (ICIS) have shown long-term good efficacy and tolerance in clinical trials. However, single drug ICIS has reached a bottleneck for advanced gastrointestinal cancer, with low response rate and poor PFS and OS. With the results of REGONIVO showing good efficacy, the treatment mode of immune combined with small molecule anti angiogenesis drugs has sprung up. The purpose of this study was to analyze the efficacy and safety of in Camrelizumab combination with Apatinib mesylate in advanced gastrointestinal cancer.

Conditions

• Gastrointestinal Cancer
• Immunotherapy
• Targeted Therapy

Interventions

Type	Name	Description
DRUG	Camrelizumab	Camrelizumab ，200mg/㎡，d1，ivgtt，every 21 days as a cycle
DRUG	Apatinib Mesylate	Apatinib Mesylate，250mg/㎡，po，d1-5 on/d2 off，every 21 days as a cycle

Timeline

• Start date: 2019-01-01
• Primary completion: 2022-02-01
• Completion: 2022-10-01
• First posted: 2022-02-07
• Last updated: 2022-02-07

Locations

1 site across 1 country: China